FDA Approves Revumenib for Relapsed or Refractory Acute Leukaemia with a KMT2A Translocation By Ogkologos - December 10, 2024 794 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the AUGMENT-101 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Joins WHO Global Clinical Trials Forum to Strengthen Global Oncology Research Ecosystems EMA Recommends Extension of Therapeutic Indications for Enfortumab Vedotin Selinexor plus Ruxolitinib Reduces Spleen Volume, but Does Not Improve Symptom Responses Over Ruxolitinib in Patients with JAK Inhibitor-Naïve Myelofibrosis MOST POPULAR How to Strengthen Your Immune System: Part 1 September 17, 2020 Trial Produces Practice-Changing Findings for Some Children, Young Adults with Leukemia June 14, 2018 EMA Recommends Granting a Conditional Marketing Authorisation for Nadofaragene Firadenovec April 24, 2026 Adjuvant Abemaciclib Combined with Endocrine Therapy Improves IDFS in HR-Positive, HER2−Negative,... October 19, 2021 Load more HOT NEWS Can cancer cells communicate? Our COVID-19 Response: How We’re Supporting Frontline Workers At Revolution Foods Many Men with Penile Cancer Do Not Get Recommended Treatments, Study... Elliot Colburn MP: Why Cancer Research UK’s Manifesto for Cancer Research...
